tiziana-logo.png
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
March 05, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
tiziana-logo.png
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
January 08, 2024 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
tiziana-logo.png
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024 09:30 ET | Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
tiziana-logo.png
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
January 05, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist
tiziana-logo.png
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
cmi_logo.png
[Latest] Global Naloxone Market Size/Share Worth USD 2,470.2 Million by 2032 at a 11% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
December 04, 2023 14:30 ET | Custom Market Insights
Austin, TX, USA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Naloxone Market Size, Trends and Insights By Type (Injectable, Intranasal), By...
tiziana-logo.png
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023 07:09 ET | Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
November 30, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
November 01, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
October 18, 2023 07:00 ET | Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...